• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纯化的I类主要组织相容性复合体分子在体外无细胞系统中可抑制活化的自然杀伤细胞。

Purified MHC class I molecules inhibit activated NK cells in a cell-free system in vitro.

作者信息

Kambayashi T, Michaëlsson J, Fahlén L, Chambers B J, Sentman C L, Kärre K, Ljunggren H G

机构信息

Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.

出版信息

Eur J Immunol. 2001 Mar;31(3):869-75. doi: 10.1002/1521-4141(200103)31:3<869::aid-immu869>3.0.co;2-a.

DOI:10.1002/1521-4141(200103)31:3<869::aid-immu869>3.0.co;2-a
PMID:11241292
Abstract

Natural killer cells have been shown to interact with MHC class I molecules via inhibitory receptors. However, it is not known whether the inhibition induced by MHC class I molecules requires other NK cell-target cell interactions. Thus, we examined whether purified MHC class I molecules alone were able to inhibit NK cell function. Purified H-2K(b) and H-2D(b) molecules inhibited the release of IFN-gamma from spleen (H-2(b))-derived lymphokine-activated killer (LAK) cell cultures stimulated by anti-NK1.1 antibody in a concentration-dependent manner. LAK cells generated from newborn mice that express low levels of MHC class I binding Ly49 inhibitory receptors were significantly less sensitive to inhibition by H-2K(b) compared to LAK cells from adult mice. Furthermore, LAK cells generated from spleen cells of Ly49C-transgenic mice were significantly more sensitive to inhibition by H-2K(b) compared to non-transgenic littermates. Taken together, the data indicate that MHC class I induced inhibition of NK cell mediated effector functions, as assessed by IFN-gamma release after NK1.1 triggering, does not require additional cell surface molecules other than MHC class I.

摘要

自然杀伤细胞已被证明可通过抑制性受体与MHC I类分子相互作用。然而,尚不清楚MHC I类分子诱导的抑制作用是否需要其他自然杀伤细胞与靶细胞的相互作用。因此,我们研究了单独的纯化MHC I类分子是否能够抑制自然杀伤细胞功能。纯化的H-2K(b)和H-2D(b)分子以浓度依赖的方式抑制抗NK1.1抗体刺激的脾(H-2(b))来源的淋巴因子激活的杀伤(LAK)细胞培养物中IFN-γ的释放。与成年小鼠的LAK细胞相比,由表达低水平MHC I类结合Ly49抑制性受体的新生小鼠产生的LAK细胞对H-2K(b)抑制的敏感性明显较低。此外,与非转基因同窝小鼠相比,由Ly49C转基因小鼠的脾细胞产生的LAK细胞对H-2K(b)抑制的敏感性明显更高。综上所述,数据表明,如通过NK1.1触发后IFN-γ释放评估的那样,MHC I类诱导的对自然杀伤细胞介导的效应功能的抑制作用,除了MHC I类之外不需要其他细胞表面分子。

相似文献

1
Purified MHC class I molecules inhibit activated NK cells in a cell-free system in vitro.纯化的I类主要组织相容性复合体分子在体外无细胞系统中可抑制活化的自然杀伤细胞。
Eur J Immunol. 2001 Mar;31(3):869-75. doi: 10.1002/1521-4141(200103)31:3<869::aid-immu869>3.0.co;2-a.
2
A role for the src family kinase Fyn in NK cell activation and the formation of the repertoire of Ly49 receptors.Src家族激酶Fyn在自然杀伤细胞激活及Ly49受体库形成中的作用。
Eur J Immunol. 2002 Mar;32(3):773-82. doi: 10.1002/1521-4141(200203)32:3<773::AID-IMMU773>3.0.CO;2-U.
3
Host MHC class I molecules modulate in vivo expression of a NK cell receptor.宿主主要组织相容性复合体I类分子调节自然杀伤细胞受体的体内表达。
J Immunol. 1994 Sep 15;153(6):2407-16.
4
Cumulative inhibition of NK cells and T cells resulting from engagement of multiple inhibitory Ly49 receptors.多个抑制性Ly49受体结合导致的NK细胞和T细胞的累积抑制。
J Immunol. 2001 Mar 1;166(5):3002-7. doi: 10.4049/jimmunol.166.5.3002.
5
The role of LY49 NK cell subsets in the regulation of murine cytomegalovirus infections.LY49自然杀伤细胞亚群在调节小鼠巨细胞病毒感染中的作用。
J Immunol. 1999 Jan 15;162(2):718-26.
6
A "chimeric" C57l-derived Ly49 inhibitory receptor resembling the Ly49D activation receptor.一种类似于Ly49D激活受体的“嵌合”C57l衍生Ly49抑制性受体。
Cell Immunol. 2001 Apr 10;209(1):29-41. doi: 10.1006/cimm.2001.1786.
7
The NK2.1 receptor is encoded by Ly-49C and its expression is regulated by MHC class I alleles.NK2.1受体由Ly-49C编码,其表达受MHC I类等位基因调控。
Int Immunol. 1997 Apr;9(4):533-40. doi: 10.1093/intimm/9.4.533.
8
Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection.Ly49A自然杀伤细胞受体的转基因表达赋予了I类主要组织相容性复合体(MHC)特异性抑制作用,并防止骨髓同种异体移植排斥反应。
J Exp Med. 1996 Nov 1;184(5):2037-41. doi: 10.1084/jem.184.5.2037.
9
Role of interaction between Ly49 inhibitory receptors and cognate MHC I molecules in IL2-induced development of NK cells in murine bone marrow cell cultures.Ly49抑制性受体与同源MHC I类分子之间的相互作用在白细胞介素2诱导的小鼠骨髓细胞培养物中自然杀伤细胞发育中的作用。
Immunol Lett. 2004 Jul 15;94(3):209-14. doi: 10.1016/j.imlet.2004.05.008.
10
MHC class I recognition by NK receptors in the Ly49 family is strongly influenced by the beta 2-microglobulin subunit.Ly49家族中的自然杀伤细胞(NK)受体对MHC I类分子的识别受到β2微球蛋白亚基的强烈影响。
J Immunol. 2001 Jun 15;166(12):7327-34. doi: 10.4049/jimmunol.166.12.7327.

引用本文的文献

1
Paths taken towards NK cell-mediated immunotherapy of human cancer-a personal reflection.走向自然杀伤细胞介导的人类癌症免疫治疗之路——个人反思。
Scand J Immunol. 2021 Jan;93(1):e12993. doi: 10.1111/sji.12993. Epub 2020 Nov 20.
2
Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes.肿瘤中存在 HLA-A、HLA-B、HLA-C 和 B2M 基因突变时,新抗原水平升高。
BMC Med Genomics. 2019 Jul 25;12(Suppl 6):107. doi: 10.1186/s12920-019-0544-1.
3
Challenges and future perspectives of T cell immunotherapy in cancer.
T细胞免疫疗法在癌症治疗中的挑战与未来展望
Immunol Lett. 2015 Aug;166(2):117-33. doi: 10.1016/j.imlet.2015.05.018. Epub 2015 Jun 19.
4
Combinations of immunotherapy and radiation in cancer therapy.癌症治疗中免疫疗法与放射疗法的联合应用。
Front Oncol. 2014 Nov 28;4:325. doi: 10.3389/fonc.2014.00325. eCollection 2014.
5
Human NK cells differ more in their KIR2DL1-dependent thresholds for HLA-Cw6-mediated inhibition than in their maximal killing capacity.人类自然杀伤细胞在其依赖于 KIR2DL1 的 HLA-Cw6 介导的抑制作用的阈值方面差异大于其最大杀伤能力。
PLoS One. 2011;6(9):e24927. doi: 10.1371/journal.pone.0024927. Epub 2011 Sep 19.
6
Tumor immune escape mechanisms: impact of the neuroendocrine system.肿瘤免疫逃逸机制:神经内分泌系统的影响
Cancer Immunol Immunother. 2006 Jul;55(7):749-60. doi: 10.1007/s00262-006-0126-x. Epub 2006 Jan 25.
7
Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?有效的癌症免疫疗法:是一个克服免疫抑制和免疫逃逸的问题吗?
Cancer Immunol Immunother. 2004 Oct;53(10):879-92. doi: 10.1007/s00262-004-0577-x. Epub 2004 Jul 28.
8
Cancer vaccines: progress reveals new complexities.癌症疫苗:进展揭示了新的复杂性。
J Clin Invest. 2002 Aug;110(3):289-94. doi: 10.1172/JCI16216.
9
Assumptions of the tumor 'escape' hypothesis.肿瘤“逃逸”假说的假设。
Semin Cancer Biol. 2002 Feb;12(1):81-6. doi: 10.1006/scbi.2001.0399.